Ankylosing Spondylitis

Subscribe to Selected New Research on Ankylosing Spondylitis

2608 relevant articles (173 outcomes, 357 trials/studies) found for this Disease

Description: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.

Also Known As:

Spondylitis, Ankylosing; Bechterew's Disease; Bechterews Disease; Marie Struempell Disease; Spondylitis, Rheumatoid; Bechterew Disease; Marie-Struempell Disease; Rheumatoid Spondylitis; Spondylarthritis Ankylopoietica

Relationship Network

Disease Context: Research Results

Musculoskeletal Diseases: 87

Bone Diseases: 2533

Spinal Diseases: 117

Spondylitis: 368

Spondylarthritis: 156

Spondylarthropathies: 230

Ankylosing Spondylitis: 2608

Joint Diseases: 1574

Arthritis: 15067

Spondylarthritis: 156

Spondylarthropathies: 230

Ankylosing Spondylitis: 2608

Ankylosis: 600

Ankylosing Spondylitis: 2608

Related Diseases

1.	Rheumatoid Arthritis
2.	Psoriatic Arthritis
3.	Osteoarthritis
4.	Arthritis (Polyarthritis)
5.	Pain (Aches)

Experts

1.	Braun, J: 43 articles (09/2008 - 06/2000)
2.	Sieper, J: 41 articles (03/2008 - 06/2000)
3.	Rudwaleit, M: 24 articles (03/2008 - 01/2001)
4.	Brandt, J: 24 articles (09/2007 - 06/2000)
5.	Listing, J: 20 articles (03/2008 - 04/2002)
6.	Sieper, Joachim: 17 articles (09/2008 - 01/2002)
7.	Haibel, H: 15 articles (03/2008 - 06/2000)
8.	Davis, John C: 12 articles (07/2008 - 05/2002)
9.	Baraliakos, X: 12 articles (03/2008 - 04/2003)
10.	Braun, Jürgen: 11 articles (09/2008 - 03/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ankylosing Spondylitis:

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/01/2008 - "PURPOSE OF REVIEW: Medical therapy of ankylosing spondylitis has improved dramatically with the advent of anti-tumor necrosis factor therapy, but nonpharmacologic therapies have long been employed to treat the condition. " 06/01/2004 - "BACKGROUND: TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS). " 11/01/2008 - "In light of the impressive efficacy of tumor necrosis factor blockers in the treatment of ankylosing spondylitis, particularly in patients with short disease duration, defining outcome parameters to monitor the structural damage of the disease has become more pertinent. " 05/01/2007 - "PURPOSE OF REVIEW: Tumor necrosis factor alpha antagonists are effective for signs and symptoms of ankylosing spondylitis. " 09/01/2006 - "Additionally, tumor necrosis factor-alpha blockers have been shown to be effective in the treatment of ankylosing spondylitis. " Order ALL the reference details at left...
2.	infliximab (Remicade)FDA Link 04/01/2003 - "Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system." 10/01/2007 - "Is low-dose infliximab every 8 weeks effective in treating ankylosing spondylitis?" 12/01/2006 - "OBJECTIVES: Infliximab has been shown to be effective in the treatment of ankylosing spondylitis (AS) when treated in a dose of 5 mg/kg at 6 weekly intervals. " 04/06/2002 - "INTERPRETATION: Our results show that treatment with infliximab is effective in patients with active ankylosing spondylitis. " 10/01/2008 - "METHODS: In the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT), a randomized, double-blind, placebo-controlled trial of the efficacy of infliximab compared with placebo, 279 patients with active AS received either placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96 (n=78) or infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose (n=201; these patients were the focus of the radiographic analyses). " Order ALL the reference details at left...
3.	TNFR-Fc fusion protein (etanercept)FDA Link 01/01/2004 - "In randomized, double-blind, placebo-controlled trials, subcutaneous etanercept 25mg twice weekly for 6-24 weeks significantly reduced disease activity in patients with active ankylosing spondylitis. " 04/01/2008 - "Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept." 12/01/2006 - "CONCLUSIONS: Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly." 01/01/2004 - "Etanercept therapy significantly improved health-related quality of life in patients with ankylosing spondylitis compared with placebo. " 05/02/2002 - "CONCLUSIONS: Treatment with etanercept for four months resulted in rapid, significant, and sustained improvement in patients with ankylosing spondylitis." Order ALL the reference details at left...
4.	Sulfasalazine (Azulfidine)FDA LinkGeneric 04/01/2006 - "Is sulfasalazine effective in ankylosing spondylitis? " 05/01/1990 - "The results suggest that sulphasalazine is effective for the treatment of patients with ankylosing spondylitis. " 05/01/1986 - "The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis." 01/01/2005 - "SELECTION CRITERIA: We evaluated randomised and quasi-randomised trials examining the efficacy of sulfasalazine on ankylosing spondylitis. " 01/08/1989 - "Observations claiming sulphasalazine to act as a remission inducing drug for ankylosing spondylitis have neither been confirmed nor ruled out by our experiences. " Order ALL the reference details at left...
5.	Methotrexate (Mexate)FDA LinkGeneric 09/01/2007 - "Is methotrexate effective for the treatment of ankylosing spondylitis?" 11/01/2002 - "Is methotrexate effective in ankylosing spondylitis?" 03/01/2007 - "No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial." 08/01/2004 - "Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial." 01/01/2001 - "There have been few well-conducted studies into the efficacy of methotrexate in Ankylosing spondylitis. " Order ALL the reference details at left...
6.	Indomethacin (Indometacin)FDA LinkGeneric 02/01/1984 - "Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis." 11/01/1990 - "188 patients of ankylosing spondylitis were treated with anti-rheumatic tablet compared with 30 patients with Indomethacin as control group. " 10/25/1985 - "Sustained-release indomethacin in the management of ankylosing spondylitis." 02/01/1984 - "The efficacy and tolerability of a new formulation of slow-release indomethacin tablet was compared in a double-blind cross-over manner with a conventional indomethacin capsule in 30 patients with ankylosing spondylitis. " 08/01/1970 - "[Therapy of ankylosing spondylitis using indomethacin]" Order ALL the reference details at left...
7.	adalimumab (Humira)FDA Link 07/01/2006 - "More patients in the adalimumab group (45.2% [94 of 208]) than in the placebo group (15.9% [17 of 107]) had at least a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index at week 12 (P < 0.001). " 04/01/2007 - "Adalimumab is given subcutaneously every 2 weeks at a dose of 40 mg. In open and placebo-controlled trials, the drug was shown to be safe and effective in ankylosing spondylitis patients. " 07/01/2008 - "METHODS: The Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS) was an ongoing 5-year study that included an initial 24-week, randomized, placebo-controlled, double-blind period. " 06/01/2009 - "OBJECTIVE: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial. " 06/01/2009 - "Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial." Order ALL the reference details at left...
8.	Diclofenac (SR 38)FDA LinkGeneric 04/28/1986 - "Efficacy of diclofenac in ankylosing spondylitis." 01/01/1993 - "Patients with active ankylosing spondylitis of at least 6 months' duration were stabilised on diclofenac 50mg, given 2, 3 or 4 times daily in a 4-week open-label run-in. " 04/28/1986 - "Diclofenac sodium, a nonsteroidal anti-inflammatory drug that is used worldwide in ankylosing spondylitis, has not yet been marketed in the United States. " 08/05/1982 - "The efficacy and tolerability of slow-release diclofenac sodium were investigated in 40 patients with ankylosing spondylitis. " 08/05/1982 - "[Treatment of ankylosing spondylitis with slow-release diclofenac sodium in a single daily dose]" Order ALL the reference details at left...
9.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/01/2002 - "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) effects in Ankylosing Spondylitis (AS) are only suspensive but because of their rapid efficacy on inflammatory symptoms they are the first-line treatment in AS. " 12/01/2007 - "Non-steroidal anti-inflammatory agents (NSAIDs) remain the mainstay of treatment for ankylosing spondylitis (AS) though one recent trial suggests that continuous as opposed to on-demand use may be superior in preventing progression of structural damage. " 08/01/2001 - "OBJECTIVE: To develop criteria for symptomatic improvement in patients with ankylosing spondylitis (AS), using outcome domain data from placebo-controlled clinical trials of nonsteroidal antiinflammatory drugs (NSAIDs). " 03/01/1999 - "Some of the adverse events occurred only after week 6. CONCLUSION: This study suggests that a 1 yr trial might be of optimum value compared to a 6 week assessment in order to define better the efficacy and tolerability of NSAIDs in ankylosing spondylitis." 07/01/2008 - "BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the treatment of ankylosing spondylitis (AS). " Order ALL the reference details at left...
10.	Naproxen (Naprosyn)FDA LinkGeneric 04/01/1975 - "This observation suggested that naproxen might be effective in ankylosing spondylitis. " 06/01/1976 - "Naproxen in treatment of ankylosing spondylitis [Proceedings]." 04/01/1975 - "Ankylosing spondylitis: open long-term and double-blind crossover studies with naproxen." 01/01/1973 - "Naproxen in ankylosing spondylitis." 09/01/1987 - "Because of his ankylosing spondylitis naproxen was prescribed; this decreased the attacks of headache to about 50%. " Order ALL the reference details at left...

Therapies and Procedures

1.	Osteotomy 08/01/2009 - "Functional outcome was improved after lumbar closing wedge osteotomy in ankylosing spondylitis." 01/01/2008 - "OBJECT: The object of this study was to assess the effectiveness of preoperative planning in the restoration of balance and view angle in patients treated with lumbar osteotomy in ankylosing spondylitis (AS). " 01/01/2006 - "AIM: The following study describes a technique for preoperative planning and computer-assisted correction osteotomy in the treatment of ankylosing spondylitis. " 01/01/2005 - "STUDY DESIGN: A historic cohort to determine short-term complications after 115 corrective osteotomies of the cervical and lumbar spine in patients with ankylosing spondylitis. " 08/01/2009 - "Functional outcome after lumbar closing wedge osteotomy in ankylosing spondylitis." Order ALL the reference details at left...
2.	Balneology 07/01/2005 - "AIMS: This study is designed to show the efficacy of balneotherapy and balneotherapy (BT) + nonsteroid antiinflammatory drug (NSAID) use in Ankylosing spondylitis (AS) patients. " 07/01/2006 - "The effect of balneotherapy on patients with ankylosing spondylitis." 07/01/2005 - "Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy." 06/01/1981 - "[New aspects in the comprehensive balneotherapy of Bechterew's disease]" 03/16/1979 - "[Muscular changes in ankylosing spondylitis and the the effect of comprehensive balneotherapy (author's transl)]" Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 07/01/2007 - "OBJECTIVES: To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice. " 07/01/2007 - "Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion." 01/01/1996 - "Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device." 06/04/1991 - "[Drug therapy of ankylosing spondylitis]" 08/05/1982 - "The necessity of balneophysical therapy in ankylosing spondylitis is emphasized, which in most cases will only be possible in combination with adequate drug therapy." Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 11/01/2009 - "Before and after treatment, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was measured, and all patients completed the International Index of Erectile Function (IIEF) questionnaire, a self-administered measure of sexual dysfunction with five domains: erectile function (EF), intercourse satisfaction (IS), orgasmic function (OF), sexual desire (SD) and overall satisfaction (OS). " 04/01/2007 - "Readers scored each set of MRI 3 times, using 3 different methods including the Ankylosing Spondylitis spine Magnetic Resonance Imaging-activity [ASspiMRI-a, grading activity (0-6) per vertebral unit in 23 units]; the Berlin modification of the ASspiMRI-a; and the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system, which scores the 6 vertebral units considered by the reader as the most abnormal, with additional scores for "depth" and "intensity." Both the order of the methods used by each reader and the timepoints (before/after treatment) were randomized. " 12/10/1991 - "The authors briefly review the principle of the treatment and present the results of a study on the level of pain in patients with Bechterew's disease before and after treatment." 09/01/2003 - "MAIN OUTCOME MEASURES: Both groups were evaluated and compared for pain, functional and psychological status before treatment, at the end of treatment and three months after treatment using a visual analogue scale (VAS) for pain, Beck Depression Scale and Bath Ankylosing Spondylitis Functional Index (BASFI). " 08/15/2006 - "OBJECTIVE: To examine whether clinical benefits observed after treatment with infliximab were accompanied by improvement in productivity and reduction in time lost from work in a randomized, double-blind, placebo-controlled, multicenter trial of patients with ankylosing spondylitis (AS). " Order ALL the reference details at left...
5.	Climatotherapy 07/01/2005 - "CONCLUSIONS: Climatotherapy at the Dead Sea area can improve the condition of patients suffering from long-standing ankylosing spondylitis." 07/01/2005 - "OBJECTIVE: To study the efficacy of balneotherapy and climatic therapy (climatotherapy) at the Dead Sea area in patients with ankylosing spondylitis. " 02/01/2006 - "In the last two decades balneotherapy and climatotherapy have been shown to be effective in cases of inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and non-inflammatory arthritis such as osteoarthritis and fibromyalgia. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Ankylosing Spondylitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 173 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>